Rhizoxin is a potent anti-cancer agent currently being tested in human clinical trials. New methodology via symchiral cycloheptadienyl sulfone was developed that would allow synthetic access to anticancer agents. Synthesis of key segments of rhizoxin; C12–C18 and C3–C9 was studied for ultimately its total synthesis. Especially cycloheptadienyl stereodiads were used as precursors of termini-differentiated seven carbon arrays of stereotetrads and stereopentads. New efficient ways to various polypropionate stereopentads were investigated. |